Fig. 1.

CTRP9-281, a 45 residues-containing polypeptide, possesses cellular salvage kinase activation property and improves CBSC function comparable as that of gCTRP9. A/B: Effect of gCTRP9, CTRP9-237, CTRP9-277 and CTRP9-281 (2 μg/mL for 15 min) on cell salvage kinase activation in CBSC. n = 4/group, **P < 0.01 vs. vehicle. C: CBSCs proliferation curves (n = 12/group, **P < 0.01 vs. vehicle at indicated time. D/E, Wound healing assay was performed 24 h after vehicle, gCTRP9 or CTRP9-281 treatment. n = 6/group *P < 0.05 vs. vehicle. F-I: CBSCs apoptosis was determined by TUNEL staining and caspase cleavage. CBSCs were treated with 2 μg/mL gCTRP9 or 2 μg/mL CTRP9-281 for 24h followed by H₂O₂ for 2 h n = 6/group. *P < 0.05, **P < 0.01 vs. vehicle. DAPI, 4′-6-diamidino-2-phenylindole; gCTRP9, globular domain isoform of C1q/tumor necrosis factor–related protein-9; CTRP9-281, 45 residues-containing polypeptides of gCTRP9; O.D., optical density; and TUNEL, transferase-mediated dUTP nick-end labeling.